Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)

被引：0
|
作者：
Vermersch, P. [1 ]
Eralinna, J. [2 ]
Nicholas, R. [3 ,4 ]
Oreja-Guevara, C. [5 ]
Siva, A. [6 ]
Van Wijmeersch, B. [7 ,8 ]
Wiendl, H. [9 ]
Buffels, R. [10 ]
Wei, W. [10 ]
Comi, G. [11 ]
机构：
[1] Univ Lille, Lille, France
[2] NEO Res, Turku, Finland
[3] Imperial Coll Healthcare NHS Trust, London, England
[4] Imperial Coll, London, England
[5] Hosp Clin San Carlos, Madrid, Spain
[6] Istanbul Univ, Cerrahpasa Fac Med, Cerrahpasa, Turkey
[7] Univ Hasselt, Overpelt, Belgium
[8] Rehabil & MS Ctr, Overpelt, Belgium
[9] Univ Munster, Munster, Germany
[10] F Hoffmann Roche Ltd, Basel, Switzerland
[11] Univ Vita Salute San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P035
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [21] Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis
    Lucchetta, Rosa C.
    Leonart, Leticia P.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 7 - 15
  • [22] Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
    Martinez-Lopez, Iciar
    Maurino, Jorge
    Sanmartin-Fenollera, Patricia
    Ontanon-Nasarre, Ana
    Santiago-Perez, Alejandro
    Moya-Carmona, Isabel
    Gustavo Garcia-Collado, Carlos
    Fernandez-Del Olmo, Raquel
    Garcia-Arcelay, Elena
    Sarmiento, Monica
    Carreno, Agata
    Perez-Encinas, Montserrat
    PHARMACY, 2020, 8 (02)
  • [23] Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Comparison of Their Efficacy for Reducing Relapse Rate
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 34 - 35
  • [24] Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO
    Oreja-Guevara, C.
    Benedict, R. H.
    Comi, G.
    Cutter, G.
    Kister, I.
    Siva, A.
    Wiendl, H.
    Van Wijmeersch, B.
    Wuerfel, J.
    El Azzouzi, B.
    Buffels, R.
    Dirks, P.
    Kuenzel, T.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 327 - 329
  • [25] COST-EFFECTIVENESS OF FIRST-LINE DISEASE-MODIFYING THERAPIES (DMTs) FOR RELAPSING-REMITTING MS (RAMS)
    Soini, E. J.
    Joutseno, J.
    Somelahti, M.
    VALUE IN HEALTH, 2015, 18 (07) : A756 - A756
  • [26] Year one interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior diseasemodifying treatments
    Leist, T. P.
    Reder, A. T.
    Bermel, R.
    Weinstock-Guttman, B.
    Freedman, M. S.
    Cutter, G.
    Stankiewicz, J.
    Zheng, H.
    Musch, B.
    Csoboth, C.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 318 - 319
  • [27] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    PLOS ONE, 2017, 12 (10):
  • [28] Ocrelizumab treatment in patients with rrms who had a suboptimal response with one or more prior disease-modifying therapies: chords 2-year results
    Weinstock-Guttman, B.
    Bermel, R.
    Cutter, G.
    Freedman, M.
    Leist, T.
    Pei, J.
    Kile, D.
    Musch, B.
    Reder, A.
    Wolinsky, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 225 - 226
  • [29] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results)
    Fox, E. J.
    Bass, A. D.
    Aldridge, J.
    Evans, E.
    Lebson, L. A.
    Robertson, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 700 - 701
  • [30] Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies
    Bizon, Anna
    Chojdak-Lukasiewicz, Justyna
    Koltuniuk, Aleksandra
    Budrewicz, Slawomir
    Pokryszko-Dragan, Anna
    Piwowar, Agnieszka
    ANTIOXIDANTS, 2022, 11 (12)
12345